Sodium 4-aminosalicylate

Sodium p-aminosalicylate. Its chemical name is: 4-amino-2-hydroxybenzoic acid sodium salt dihydrate. Molecular formula: C7H6NNaO32H2O, molecular weight: 211.14.

1. Para-aminobenzoic acid and this product have antagonistic effects, and the two should not be used together. 2. This product can enhance the effect of anticoagulants (coumarin or indandione derivatives), so the dose of oral anticoagulants should be appropriately adjusted when using para-aminosalicylic acid or after using it. 3. When used in combination with ethionamide, adverse reactions may increase. 4. The combination of probenecid or sulfinpyrazone with aminosalicylic acid can reduce the secretion of the latter from the renal tubules, leading to increased blood drug concentrations, prolonged duration, and toxic reactions. Therefore, when aminosalicylic acid is used in combination with probenecid or sulfinpyrazone or after the combination, the dose of the former should be appropriately adjusted, and the patient should be closely followed up. However, most people do not use probenecid as an auxiliary drug for aminosalicylic acid treatment. 5. Aminosalicylic acid may affect the absorption of rifampicin, resulting in a decrease in the blood concentration of rifampicin. Patients must be informed that they should be at least 6 hours apart when taking the above two drugs. 6-Aminosalicylates and vitamin B12 can affect the absorption of the latter from the gastrointestinal tract when taken together. Therefore, patients taking aminosalicylic acids may have an increased requirement for vitamin B12.

Sodium p-aminosalicylate. Its chemical name is: 4-amino-2-hydroxybenzoic acid sodium salt dihydrate. Molecular formula: C7H6NNaO32H2O, molecular weight: 211.14.

1. Para-aminobenzoic acid and this product have antagonistic effects, and the two should not be used together. 2. This product can enhance the effect of anticoagulants (coumarin or indandione derivatives), so the dose of oral anticoagulants should be appropriately adjusted when using para-aminosalicylic acid or after using it. 3. When used in combination with ethionamide, adverse reactions may increase. 4. The combination of probenecid or sulfinpyrazone with aminosalicylic acid can reduce the secretion of the latter from the renal tubules, leading to increased blood drug concentrations, prolonged duration, and toxic reactions. Therefore, when aminosalicylic acid is used in combination with probenecid or sulfinpyrazone or after the combination, the dose of the former should be appropriately adjusted, and the patient should be closely followed up. However, most people do not use probenecid as an auxiliary drug for aminosalicylic acid treatment. 5. Aminosalicylic acid may affect the absorption of rifampicin, resulting in a decrease in the blood concentration of rifampicin. Patients must be informed that they should be at least 6 hours apart when taking the above two drugs. 6-Aminosalicylates and vitamin B12 can affect the absorption of the latter from the gastrointestinal tract when taken together. Therefore, patients taking aminosalicylic acids may have an increased requirement for vitamin B12.